ITEM 8.01 Other Events

On January 24, 2022, Soleno Therapeutics, Inc. (the Company) issued a press release discussing recent regulatory guidance from the U.S. Food and Drug Administration's Division of Psychiatry regarding the development of the Company's once-daily DCCR (diazoxide choline) extended release tablets, a once daily oral tablet for the treatment of Prader-Willi syndrome (PWS), which is currently being evaluated in a Phase 3 clinical development program.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

ITEM 9.01 Financial Statements and Exhibits




(d)  Exhibits



Exhibit
  No.       Description

99.1          Press release issued by Soleno Therapeutics, Inc. dated January 24,
            2022

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses